http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 07:09:07 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Edwards+Lifesciences+%28EW%29+PT+Raised+to+%2495+at+Truist+Securities/26776573.html Truist Securities analyst Richard Newitter raised the price target on Edwards Lifesciences (NYSE: EW) to $95.00 (from $90.00) while maintaining a Hold rating. http://www.streetinsider.com/Analyst+PT+Change/Edwards+Lifesciences+%28EW%29+PT+Raised+to+%2495+at+Truist+Securities/26776573.html Thu, 16 Jul 2026 07:09:07 -0400 EW http://www.streetinsider.com/Press+Releases/Edwards+Lifesciences+to+Host+Earnings+Conference+Call+on+July+23%2C+2026/26776534.html <p> IRVINE, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify">Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.</p><p>To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.edwards.com&amp;esheet=54571460&amp;newsitemid=20260716585231&amp;lan=en-US&amp;anchor=ir.edwards.com&amp;index=3&amp;md5=b5a3e4da3b03171f793ddb3884cc98df" shape="rect">ir.edwards.com</a>.</p><p><b><span class="bwuline">About Edwards Lifesciences</span></b></p><p>Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to http://www.streetinsider.com/Press+Releases/Edwards+Lifesciences+to+Host+Earnings+Conference+Call+on+July+23%2C+2026/26776534.html Thu, 16 Jul 2026 07:05:00 -0400 EW O.00073416 http://www.streetinsider.com/Press+Releases/Edwards+Lifesciences+to+Host+Earnings+Conference+Call+on+July+23%2C+2026/26776534.html <p> IRVINE, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify">Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.</p><p>To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.edwards.com&amp;esheet=54571460&amp;newsitemid=20260716585231&amp;lan=en-US&amp;anchor=ir.edwards.com&amp;index=3&amp;md5=b5a3e4da3b03171f793ddb3884cc98df" shape="rect">ir.edwards.com</a>.</p><p><b><span class="bwuline">About Edwards Lifesciences</span></b></p><p>Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to http://www.streetinsider.com/Press+Releases/Edwards+Lifesciences+to+Host+Earnings+Conference+Call+on+July+23%2C+2026/26776534.html Thu, 16 Jul 2026 07:05:00 -0400 EW O.00073416 http://www.streetinsider.com/Business+Wire/Edwards+Lifesciences+to+Host+Earnings+Conference+Call+on+July+23%2C+2026/26776534.html <p> IRVINE, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify">Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.</p><p>To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.edwards.com&amp;esheet=54571460&amp;newsitemid=20260716585231&amp;lan=en-US&amp;anchor=ir.edwards.com&amp;index=3&amp;md5=b5a3e4da3b03171f793ddb3884cc98df" shape="rect">ir.edwards.com</a>.</p><p><b><span class="bwuline">About Edwards Lifesciences</span></b></p><p>Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to http://www.streetinsider.com/Business+Wire/Edwards+Lifesciences+to+Host+Earnings+Conference+Call+on+July+23%2C+2026/26776534.html Thu, 16 Jul 2026 07:05:00 -0400 EW O.00073416 http://www.streetinsider.com/Business+Wire/Edwards+Lifesciences+to+Host+Earnings+Conference+Call+on+July+23%2C+2026/26776534.html <p> IRVINE, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify">Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.</p><p>To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.edwards.com&amp;esheet=54571460&amp;newsitemid=20260716585231&amp;lan=en-US&amp;anchor=ir.edwards.com&amp;index=3&amp;md5=b5a3e4da3b03171f793ddb3884cc98df" shape="rect">ir.edwards.com</a>.</p><p><b><span class="bwuline">About Edwards Lifesciences</span></b></p><p>Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to http://www.streetinsider.com/Business+Wire/Edwards+Lifesciences+to+Host+Earnings+Conference+Call+on+July+23%2C+2026/26776534.html Thu, 16 Jul 2026 07:05:00 -0400 EW O.00073416 http://www.streetinsider.com/Analyst+PT+Change/Edwards+Lifesciences+%28EW%29+PT+Raised+to+%24105+at+Mizuho/26770530.html Mizuho analyst Anthony Petrone raised the price target on Edwards Lifesciences (NYSE: EW) to $105.00 (from $100.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Edwards+Lifesciences+%28EW%29+PT+Raised+to+%24105+at+Mizuho/26770530.html Wed, 15 Jul 2026 06:39:47 -0400 EW http://www.streetinsider.com/Analyst+PT+Change/Edwards+Lifesciences+%28EW%29+PT+Raised+to+%2494+at+Baird/26764373.html Baird analyst David Rescott raised the price target on Edwards Lifesciences (NYSE: EW) to $94.00 (from $87.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Edwards+Lifesciences+%28EW%29+PT+Raised+to+%2494+at+Baird/26764373.html Tue, 14 Jul 2026 06:25:00 -0400 EW http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Edwards+Lifesciences++++++For%3A+Jul+11++Filed+by%3A+Bruls+Annette/26762545.html si-local-file:///var/storage/secattach/20260713/26762545.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Edwards+Lifesciences++++++For%3A+Jul+11++Filed+by%3A+Bruls+Annette/26762545.html Mon, 13 Jul 2026 16:09:00 -0400 EW O.00073416 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Edwards+Lifesciences++++++For%3A+Jul+11++Filed+by%3A+Bruls+Annette/26762545.html si-local-file:///var/storage/secattach/20260713/26762545.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Edwards+Lifesciences++++++For%3A+Jul+11++Filed+by%3A+Bruls+Annette/26762545.html Mon, 13 Jul 2026 16:09:00 -0400 EW O.00073416 http://www.streetinsider.com/Analyst+PT+Change/Edwards+Lifesciences+%28EW%29+PT+Raised+to+%24110+at+RBC+Capital/26759675.html RBC Capital analyst Shagun Singh raised the price target on Edwards Lifesciences (NYSE: EW) to $110.00 (from $100.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Edwards+Lifesciences+%28EW%29+PT+Raised+to+%24110+at+RBC+Capital/26759675.html Mon, 13 Jul 2026 07:12:44 -0400 EW http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html <p>At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.</p><p>The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”</p><p>While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to http://www.streetinsider.com/Hot+List+Pro/U.S.+MedTech+stocks%3A+Q2+earnings+preview/26758576.html Sun, 12 Jul 2026 10:00:00 -0400 ABT DXCM EW GEHC HAE ISRG SYK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Edwards+Lifesciences++++++For%3A+Jul+09++Filed+by%3A+Mistras+Theodora/26758007.html si-local-file:///var/storage/secattach/20260710/26758007.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Edwards+Lifesciences++++++For%3A+Jul+09++Filed+by%3A+Mistras+Theodora/26758007.html Fri, 10 Jul 2026 17:11:00 -0400 EW O.00073416